If approved, it would be the first major new drug treatment for Parkinson’s in half a century. Richard Mailman, a University ...

In this video, Andres Deik, MD, MSEd, FAAN, discusses the results of the CYCLE-II trial, presented at the 2025 International Congress of Parkinson’s Disease and Movement Disorders.

Glovadalen, a novel D1 receptor positive allosteric modulator, is linked to improve OFF time in patients with Parkinson’s ...

The 21st century has seen no great leaps forward in the hunt for a way to slow, stop or reverse the relentless progression of ...

Degradation studies indicated that about 82% of the implants disintegrated within seven days. Complete degradation of the ...

Parkinson’s disease currently affects nearly one million Americans with no specific known cause and no cure. Treatments have come a long way over the past few decades focusing on managing symptoms and ...

For neurologist and movement disorder specialist Dr. Jill Giordano Farmer, the fight against Parkinson’s isn’t just ...

Medically reviewed by Erika Prouty, PharmD Key Takeaways Always ask your healthcare provider before starting a new supplement if you are on prescription medications.Some supplements can reduce the ...

Subthalamic deep brain stimulation is an effective long-term therapy for Parkinson disease, according to a recent study.

Skin conditions with Parkinson’s disease are common and manageable. By paying attention to these symptoms, patients can ...